Ascletis moves ASC30 into diabetes as Phase 2 readout nears in Q3 2026
The oral GLP-1R agonist already posted positive obesity data; a 100-patient diabetes trial now tests whether that HbA1c-lowering profile extends to a second indication.
Executive Summary
- Ascletis has finished enrolling a placebo-controlled Phase 2 study testing whether its oral GLP-1R agonist lowers blood sugar in type 2 diabetes, extending a drug that already showed benefit in obesity into a second indication.
- The trial moved from recruiting to active and enrolled to its full target without any change to its primary endpoint or timeline, a clean operational execution rather than a story of delay or shortfall.
- A positive HbA1c result would support Ascletis's plan to position an oral, once-daily pill as an alternative to the injectable GLP-1 drugs that dominate diabetes and obesity care, while a null result would confine the asset's validated benefit to obesity alone.
- No trial in this indication currently pairs the same GLP-1 receptor target with an oral small-molecule route, leaving ASC30 to be judged mainly against the injectable peptide class rather than a direct oral rival.
The trial
Ascletis Pharma Inc. announced on April 26, 2026 that it completed enrollment in a 13-week, randomized, double-blind, placebo-controlled Phase 2 study of ASC30 tablets in participants with type 2 diabetes mellitus. The study, registered as NCT07321678, enrolled 100 participants across U.S. sites, randomized roughly 2:3:3:2 to 40 mg, 60 mg, and 80 mg ASC30 or matching placebo, with doses titrated weekly from a 1 mg starting dose. The primary endpoint is the mean change from baseline in HbA1c (a marker of average blood sugar) at 13 weeks versus placebo, with fasting blood glucose and body weight change as secondary endpoints. Ascletis+1Ascletis Completes Enrollment in U.S. Phase II Study of ASC30, an Oral Small Molecule GLP-1R Agonist, for the Treatment of DiabetesApr 27, 2026A Study to Evaluate the Efficacy, Safety, and Tolerability of ASC30 Tablets in Participants With Type 2 Diabetes MellitusNCT07321678
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
The stake
Type 2 diabetes is ASC30's second indication after obesity. Ascletis chairman and chief executive Jinzi Jason Wu said the company is "expanding ASC30's clinical development into the large diabetes treatment market" as "a logical next step" following positive results announced in December 2025 from the drug's Phase 2 obesity study. Wu described ASC30 as having potential to be "best-in-class" among oral small-molecule GLP-1 agonists for obesity based on that earlier readout, and said the company expects to seek FDA clearance and start U.S. Phase 3 obesity trials by the end of the third quarter of 2026. The diabetes study is designed to test whether that efficacy and tolerability profile carries over to glycemic control. AscletisAscletis Completes Enrollment in U.S. Phase II Study of ASC30, an Oral Small Molecule GLP-1R Agonist, for the Treatment of DiabetesApr 27, 2026
Operational status
The trial's registry status moved from Recruiting to Active, not recruiting on April 30, 2026, once enrollment closed at its full 100-patient target, with no reduction or increase against the original plan. The primary completion date has stood at August 1, 2026 with zero amendments recorded to the primary completion date, the primary endpoint, or eligibility criteria, and the study's protocol-change count is zero for the year to date. That combination, full enrollment reached on schedule and a stable protocol, points to routine execution rather than any operational strain ahead of the readout. NCT07321678A Study to Evaluate the Efficacy, Safety, and Tolerability of ASC30 Tablets in Participants With Type 2 Diabetes MellitusNCT07321678
The competitive frame
Among trials sharing the GLP-1 receptor target, none currently tests an oral small-molecule agonist against placebo in type 2 diabetes the way NCT07321678 does; the nearest peers by target, such as Novo Nordisk's CagriSema and AstraZeneca's oral GLP-1R candidate elecoglipron, sit in Phase 3 for related metabolic indications rather than head-to-head in this same trial population. The broader type 2 diabetes field remains dominated by injectable peptide GLP-1 agonists such as semaglutide, alongside SGLT2 inhibitors and other oral small molecules aimed at different targets. With no direct oral GLP-1R comparator running in this indication, the readout will be judged primarily against the injectable-drug efficacy bar and against ASC30's own obesity data rather than against a same-class oral rival.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.